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Fibrinolysis for Intermediate-Risk Pulmonary Embolism
To the Editor: In the Pulmonary Embolism 
Thrombolysis (PEITHO) study (April 10 issue),1 
a bolus of unfractionated heparin was withheld 
from 303 patients because they had just received 
subcutaneous low-molecular-weight heparin or 
fondaparinux. Low-molecular-weight heparin in 
particular has a slow onset of action, taking 4 to 
6 hours to reach full effect.2 This delay in the ef-
fect of treatment may have been unfavorable to 
patients not receiving tenecteplase, among whom 
the incidence of hemodynamic decompensation 
(often within the first day after randomization) 
was higher than that among patients receiving 
tenecteplase.
Guidelines support the safety of low-molecular-
weight heparin in patients with pulmonary em-
bolism. Caution is warranted, however, because 
the majority of relevant trials (10 of 12 trials in 
a key meta-analysis3) used low-molecular-weight 
heparin after an initial bolus of unfractionated 
heparin. Omitting this bolus may be unsafe, 
particularly in high-risk patients such as those 
involved in the PEITHO study. Previous guide-
lines have recommended a bolus of unfraction-
ated heparin before the administration of low-
molecular-weight heparin.4 Later, for some reason, 
this recommendation disappeared.
We would like to know outcome details of the 
subgroup of patients who did not receive an 
initial bolus of unfractionated heparin. If hemo-
dynamic decompensation in the placebo group 
occurred primarily in this subgroup, the expla-
nation may be a delayed onset of anticoagulant 
activity.
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To the Editor: Meyer et al. reported important 
results of a large, multicenter trial evaluating the 
effect of fibrinolysis in patients with intermediate-
risk pulmonary embolism. The authors evaluated 
interactions (i.e., different treatment effects in 
subgroups of the population) on a relative scale 
using logistic regression and found a trend to-
ward a greater risk of major extracranial bleed-
ing among patients older than 75 years of age 
(odds ratio, 20.38, vs. 2.80 among patients 75 years 
of age or younger; P = 0.09).
If the interaction had been assessed on an 
absolute scale, very different conclusions regard-
ing treatment safety in elderly patients would 
have been drawn. Indeed, among patients 75 years 
of age or younger, 14 of 344 patients in the fi-
brinolysis group (4.1%) and 5 of 335 patients in 
the placebo group (1.5%) had major bleeding, 
resulting in an absolute risk difference of 2.6 per-
centage points (95% confidence interval [CI], 
0.1 to 5.0). In contrast, among patients older 
than 75 years of age, 18 of 162 patients in the 
fibrinolysis group (11.1%) and 1 of 164 patients 
in the placebo group (0.6%) had major bleeding, 
resulting in an absolute risk difference of 10.5 
percentage points (95% CI, 5.5 to 15.5). The 
absence of overlap in the confidence intervals 
indicates that fibrinolysis was associated with a 
significantly increased absolute risk of major 
extracranial bleeding among older patients.
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To the Editor: The PEITHO investigators found 
a significant reduction in death or hemodynamic 
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decompensation with the use of fibrinolytic ther-
apy in patients with intermediate-risk pulmonary 
embolism, yet with an increase in hemorrhagic 
events. Significant variability among study par-
ticipants in response to plasminogen activators 
has been reported in healthy volunteers.1 Further-
more, this variability can be more pronounced 
in older patients2 and those with inflammatory 
conditions, given variations in levels of endog-
enous inhibitors of fibrinolysis — such as plas-
minogen activator inhibitor type 1 (PAI-1), 
thrombin-activatable fibrinolysis inhibitor, anti-
plasmin, and α2-macroglobulin — as well as di-
urnal fluctuation of PAI-1.3 We have recently 
found profound differences in ex vivo tissue plas-
minogen activator–induced fibrinolysis among 
severely injured patients, ranging from hypersen-
sitivity (hyperfibrinolysis) to complete resistance 
(fibrinolysis shutdown).4 Thromboelastography, 
which measures changes in the viscoelasticity of 
whole blood, has been validated clinically as a 
tool to quantify hyperfibrinolysis in trauma pa-
tients and to guide antifibrinolytic therapy.5 Con-
versely, a role could exist for viscoelastic assays 
to guide fibrinolytic therapy by permitting the 
adjustment of the drug dose on the basis of the 
patient’s fibrinolytic response ex vivo. Such goal-
directed therapies with the use of plasminogen 
activators have yet to emerge and could reduce 
hemorrhagic complications while ensuring effec-
tiveness, thus allowing for safe implementation 
of emerging thrombolytic therapies.
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To the Editor: Although we laud the publica-
tion of the results of the PEITHO trial, in which 
the investigators conclude that prompt fibrinoly-
sis can reduce the risk of hemodynamic decom-
pensation or death among normotensive patients 
who have pulmonary embolism with right ven-
tricular dysfunction or myocardial injury, we wish 
to raise the following concerns. The absence of a 
core laboratory for assessment of imaging of right 
ventricular dysfunction raises the possibility of a 
wide variability in the interpretation of images of 
a cardiac structure that is particularly difficult to 
evaluate by means of transthoracic echocardiog-
raphy. On multidetector computed tomographic 
(CT) pulmonary angiography, the exact image to 
be chosen for the right ventricular:left ventricular 
diameter ratio can be quite subjective. Recon-
structed CT four-chamber views are also superior 
to those from axial views.1
Because thrombolysis is associated with hem-
orrhagic complications, the use of the simplified 
Pulmonary Embolism Severity Index (PESI) score 
can identify patients at very low risk.2 It would 
be interesting to know how many patients in the 
study who were classified as having intermediate 
risk according to the European Society of Cardi-
ology criteria would be labeled as having low 
risk according to the simplified PESI score. 
Thrombolysis might not be indicated in this 
subgroup.
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To the Editor: With regard to the article by 
Meyer el al.: we would like to share some thoughts 
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regarding the development of chronic thrombo-
embolic pulmonary hypertension after submas-
sive pulmonary embolism. The overall incidence 
of chronic thromboembolic pulmonary hyper-
tension after pulmonary embolism is 2 to 4%1; 
however, no one has rigorously studied its inci-
dence after submassive pulmonary embolism. 
Kline et al.2 and Fasullo et al.3 found that pa-
tients who received up-front thrombolysis (as the 
initial therapeutic approach) had reduced right 
ventricular systolic pressures (<40 mm Hg) and 
improved function. We believe that uncertainties 
still exist regarding the potential benefit of 
thrombolysis in this particular subgroup of pa-
tients with objective quantitative echocardio-
graphic evidence of persistent pulmonary hyper-
tension. It would be helpful for clinicians if the 
authors would consider analyzing the subgroup 
of patients with persistent pulmonary hyperten-
sion, addressing the associated end point of 
chronic thromboembolic pulmonary hyperten-
sion, which confers higher mortality among sur-
vivors. We believe that by addressing the echocar-
diographic predictors of chronic thromboembolic 
pulmonary hypertension and by characterizing 
more accurately this controversial but intriguing 
phenotype of patients, clinicians may better 
 understand who will benefit most from throm-
bolysis.
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To the Editor: In his editorial about the PEITHO 
trial, Elliott1 notes that half-dose fibrinolysis has 
been studied in the management of myocardial 
infarction but not pulmonary embolism.2 We 
would like to bring the Moderate Pulmonary Em-
bolism Treated with Thrombolysis (MOPETT) 
trial3 to the attention of Journal readers.
The MOPETT trial used a definition of mod-
erate-risk pulmonary embolism that was similar 
to that used in the PEITHO study and randomly 
assigned patients to alteplase infusion or placebo, 
in addition to fractionated heparin or subcuta-
neous enoxaparin. However, unlike the PEITHO 
trial, the MOPETT trial halved the conventional 
weight-based dosing for the treatment of mas-
sive pulmonary embolism. Among the 121 pa-
tients who underwent randomization, mortality 
at index hospitalization was similar in the throm-
bolysis and control groups (1.6% and 5.0%, re-
spectively), and no bleeding complications were 
observed in either group. This trial was also 
positive for its primary outcome of decreased 
cardiovascular morbidity from pulmonary hyper-
tension at long-term follow-up. Despite a small 
sample and the need for further validation, the 
MOPETT trial suggests that half-dose throm-
bolysis may indeed be a promising, lower-risk 
therapy for patients with intermediate-risk mod-
erate pulmonary embolism.
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The authors reply: Smulders and Kramers sug-
gest that withholding the bolus of unfractionated 
heparin in patients receiving low-molecular-
weight heparin may have adversely affected out-
comes, particularly among patients in the place-
bo group. We do not believe that this was the 
case. First, the median interval between injection 
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of low-molecular-weight heparin and randomiza-
tion was 6.5 hours in the patients assigned to 
placebo. Second, hemodynamic decompensation 
or death occurred among 5.3% of patients in the 
placebo group who were receiving low-molecu-
lar-weight heparin or fondaparinux before ran-
domization, as compared with 5.5% of those 
receiving unfractionated heparin from the be-
ginning.
According to Girerd et al., if the interaction 
between the primary outcome and age had been 
assessed on an absolute scale, the interpretation 
of the subgroup analysis would have been differ-
ent. In randomized trials with binary data, the 
most frequently used measures of treatment ef-
fect are odds ratios, relative risks, and hazard 
ratios. It is generally best to avoid testing inter-
action with the use of a different type of scale 
than the one used for the primary outcome. For 
this reason, interaction tests based on the logis-
tic model were used in both the main and the 
subgroup analyses. Our results generate the hy-
pothesis that fibrinolysis may be associated with 
a lower bleeding risk among younger patients 
than among those older than 75 years of age.
Gonzalez et al. suggest that variability among 
study participants in the response to plasmino-
gen activators may account for a reduced effi-
cacy of tenecteplase in older patients. Although 
we did not perform thromboelastography in the 
PEITHO trial, the main concern arising from the 
results in patients older than 75 years of age was 
the bleeding risk rather than a lack of efficacy.
We agree with Nobre and Thomas that the 
interpretation of echocardiographic or CT find-
ings may have varied among study sites. Because 
the PEITHO study protocol permitted only a 
short delay between confirmation of right ven-
tricular dysfunction and randomization, sending 
the results to a core laboratory would have been 
highly impractical. Other possible determinants 
of outcome such as the PESI score will be ana-
lyzed in a future report.
We agree with Porres-Aguilar and Mukherjee 
that the development of chronic thromboembolic 
pulmonary hypertension is a concern in patients 
with intermediate-risk pulmonary embolism. 
Indeed, the PEITHO study may offer a good op-
portunity to address the potential role of throm-
bolytic therapy in the prevention of this compli-
cation. Patient follow-up over a period of at least 
2 years is being performed in the PEITHO popu-
lation to address these issues.
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The editorialist replies: Intracranial hemor-
rhage is a major risk of fibrinolysis. In my edito-
rial, I pointed out that half-dose tenecteplase was 
given to patients with myocardial infarction who 
were 75 years of age or older, but this reduced-
dose strategy for older patients has not been 
studied for acute pulmonary embolism. In the 
study of fibrinolysis for acute myocardial infarc-
tion, half-dose tenecteplase reduced the rate of 
intracranial hemorrhage dramatically among 
patients 75 years of age or older.1 The PEITHO 
investigators observed a higher rate of intracra-
nial hemorrhage among patients given full-dose 
tenecteplase who were older than 75 years of age 
than among younger patients.
Spiegel et al. call attention to a study of half-
dose fibrinolysis to treat adults of all ages with 
“moderate” pulmonary embolism.2 The patients 
were younger and probably had a lower risk of 
intracranial hemorrhage than the patients in the 
PEITHO trial. As Spiegel et al. note, the MOPETT 
trial does not provide compelling evidence for 
the efficacy or safety of half-dose fibrinolysis. I 
agree with their cautious statement that half-
dose thrombolysis may be a promising, lower-
risk therapy for patients at intermediate risk of 
death from acute pulmonary embolism, but one 
that requires further study.
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